ArticleACS omega2026
Molecularly Imprinted Polymer Nanoparticles for Reducing Herpes Simplex Virus Type 2 Infection.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecularly imprinted polymer nanoparticles (nanoMIPs) were synthesized via solid-phase imprinting for the selective recognition and inhibition of herpes simplex virus type 2 (HSV-2). An optimized copolymer composition yielded spherical nanoMIPs with a hydrodynamic diameter of 146 ± 4 nm, comparable to that of HSV-2 virions (94 ± 6 nm). Electrochemical analysis showed a 3-fold higher current shift for HSV-2-imprinted nanoMIPs compared to nonimprinted controls, confirming enhanced binding ability toward HSV-2. The nanoMIPs exhibited highly preferential recognition of HSV-2 over related viruses, with cross-reactivity of 62 ± 2% for HSV-1, 30 ± 1% for human papillomavirus type 16, and less than 3% for hepatitis B virus and dengue virus type 1. The cytotoxicity assay confirmed that the nanoMIPs were biocompatible with Vero cells and human primary peripheral blood mononuclear cells at concentrations up to 2.92 × 10
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.